- Home
- SCLX vs CNF Comparison
SCLX vs CNF Comparison
Compare SCLX & CNF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SCLX
- CNF
- Stock Information
- Founded
- SCLX 2011
- CNF 1999
- Country
- SCLX United States
- CNF China
- Employees
- SCLX N/A
- CNF N/A
- Industry
- SCLX Biotechnology: Pharmaceutical Preparations
- CNF Finance: Consumer Services
- Sector
- SCLX Health Care
- CNF Finance
- Exchange
- SCLX Nasdaq
- CNF Nasdaq
- Market Cap
- SCLX 35.7M
- CNF 35.7M
- IPO Year
- SCLX N/A
- CNF 2018
- Fundamental
- Price
- SCLX $26.28
- CNF $3.00
- Analyst Decision
- SCLX Strong Buy
- CNF
- Analyst Count
- SCLX 3
- CNF 0
- Target Price
- SCLX $367.50
- CNF N/A
- AVG Volume (30 Days)
- SCLX 230.4K
- CNF 97.1K
- Earning Date
- SCLX 08-13-2025
- CNF 08-28-2025
- Dividend Yield
- SCLX N/A
- CNF N/A
- EPS Growth
- SCLX N/A
- CNF N/A
- EPS
- SCLX N/A
- CNF N/A
- Revenue
- SCLX $44,236,000.00
- CNF $50,241,013.00
- Revenue This Year
- SCLX $89.26
- CNF $252.34
- Revenue Next Year
- SCLX $203.95
- CNF N/A
- P/E Ratio
- SCLX N/A
- CNF N/A
- Revenue Growth
- SCLX N/A
- CNF N/A
- 52 Week Low
- SCLX $3.60
- CNF $2.36
- 52 Week High
- SCLX $41.30
- CNF $28.40
- Technical
- Relative Strength Index (RSI)
- SCLX 76.74
- CNF 37.10
- Support Level
- SCLX $23.90
- CNF $2.36
- Resistance Level
- SCLX $19.73
- CNF $3.59
- Average True Range (ATR)
- SCLX 1.85
- CNF 0.99
- MACD
- SCLX 0.50
- CNF -0.05
- Stochastic Oscillator
- SCLX 91.79
- CNF 16.45
About SCLX Scilex Holding Company
Scilex Holding Co is focused on acquiring, developing, and commercializing non-opioid pain management products for the treatment of acute and chronic pain. The Company's commercial product, ZTlido (lidocaine topical system), is a prescription lidocaine topical product for relieving pain associated with postherpetic neuralgia, which is a form of post-shingles nerve pain. It is focused on commercializing Gloperba (colchicine USP) an oral solution, a prophylactic treatment for painful gout flares in adults. The Company's three product candidates are SP-102 or SEMDEXA viscous gel formulation of a used corticosteroid for epidural injections, SP-103 a Phase 2, triple-strength formulation of ZTlido, and SP-104, 4.5 mg Delayed Burst Release Low Dose Naltrexone Hydrochloride (DBR-LDN) Capsule.
About CNF CNFinance Holdings Limited each representing twenty (20)
CNFinance Holdings Ltd is an equity loan service provider. It focuses on the development of small and micro-enterprises. It generates revenue in the form of interest and financing service fees on loans and interest on deposits with banks. Its primary target borrower segment is MSE owners who own real properties in Tier 1 and Tier 2 cities in China. Geographically, it has an operation in PRC.